Skip to content

Generate Biomedicines, Inc.

GENB

CIK 0002100782

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
—
Q1 Apr 2026
EPS Diluted (TTM)
—
Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
—
Q1 Apr 2026
Cash
$160.58M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
128.19M sh
Q1 Apr 2026

Recent filings